StartHPX • FRA
add
Hisamitsu Pharmaceutical Co Inc
Seneste lukkekurs
25,60 €
Dagsinterval
25,80 € - 25,80 €
Årsinterval
21,00 € - 28,80 €
Markedsværdi
364,25 mia. JPY
Gns. volumen
6,00
P/E-værdi
-
Udbytteprocent
-
Primær børs
TYO
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(JPY) | aug. 2024info | År til år-ændring |
---|---|---|
Indtægt | 39,65 mia. | 13,66 % |
Driftsudgifter | 18,75 mia. | 17,95 % |
Nettoindtægt | 4,31 mia. | -1,33 % |
Overskudsgrad | 10,87 | -13,18 % |
Earnings per share | — | — |
EBITDA | 6,35 mia. | 20,49 % |
Effektiv afgiftssats | 28,38 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(JPY) | aug. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 122,74 mia. | -13,22 % |
Samlede aktiver | 350,48 mia. | 1,79 % |
Samlede passiver | 74,55 mia. | 7,74 % |
Samlet egenkapital | 275,92 mia. | — |
Shares outstanding | 73,34 mio. | — |
Kurs/indre værdi | 0,01 | — |
Afkast af aktiver | 3,52 % | — |
Afkast af kapital | 4,46 % | — |
Pengestrøm
Nettoændring i likviditet
(JPY) | aug. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 4,31 mia. | -1,33 % |
Pengestrøm fra drift | — | — |
Pengestrøm fra investering | — | — |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | — | — |
Fri pengestrøm | — | — |
Om
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
Grundlagt
1847
Hovedkvarter
Website
Ansatte
2.759